[[PF-184563]]

CATEGORIES: Hormonal agents, Pfizer

PF-184563 is a potent, selective non-peptidic antagonist of the V1a receptor.[tpl]cite journal | author = Johnson PS, Ryckmans T, Bryans J, Beal DM, Dack KN, Feeder N, Harrison A, Lewis M, Mason HJ, Mills J, Newman J, Pasquinet C, Rawson DJ, Roberts LR, Russell R, Spark D, Stobie A, Underwood TJ, Ward R and Wheeler S | title = Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability| journal = Bioorganic. Med. Chem. Lett. | issue = 21 | pages = 5684–5687|date=October 2011| pmid = 21885275 | doi = 10.1016/j.bmcl.2011.08.038[/tpl] The compound was discovered by Pfizer in its Sandwich, Kent research center, as a potential treatment for dysmenorrhoea, an indication for which V1a antagonists have shown efficacy.[tpl]cite journal | author = Brouard R, Bossmar T, Fournie-Lloret D, Chassard D and Akerlund M | title = Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea| journal = Br. J. Obstet. Gynaecol. | issue = 107 | volume = 5|pages = 614–619| year = 2000 | pmid = 10826575 | doi = 10.1111/j.1471-0528.2000.tb13302.x[/tpl]

==References==


